[ 161 tb]tb psma
PeptideexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 29, 2022 (NCT05521412)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIRadiopharmaceutical
FOLH1 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 161-terbium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05521412 | Phase 1/Phase 2 (Phase 2) | Sep 29, 2022 | Peter MacCallum Cancer Centre |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1